University of Tennessee Health Science Center College of Pharmacy

Company

Related News

$3.2 million project targets MDM2 in triple-negative breast cancer

Apr 23, 2026

A $3.2 million research collaboration is developing a drug that directly breaks down MDM2 in triple-negative breast cancer. Early laboratory models showed tumour shrinkage, and the team is studying dosing, safety and performance.

UH Researcher Joins $3.2M Effort to Develop Triple-Negative Breast Cancer Drug

Mar 14, 2026

A University of Houston researcher has joined a $3.2 million effort to develop a new drug targeting MDM2, a cancer-driving protein in triple-negative breast cancer. The compound has shown ability to shrink tumors in early laboratory models.